Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

BY EMAIL

23rd March 2015

RE: ACD Consultees & Commentators: (Hepatitis C (chronic) - ledipasvir-sofosbuvir) [742]

Dear Meindert,

Thank you for giving us the opportunity to comment on the ACD for the above appraisal. We have included our comments below.

- Section 3.4:
  For clarification, Peginterferon alfa-2a was the peginterferon used in ADVANCE and peginterferon alfa-2b was used for SPRINT-2.

- Table 10:
  The row in table 10 '*PEG-IFN2a+RBV'* should also include peginteferon alfa-2b + RBV, or could include a general indication of peginterferon alfa. This same comment applies under all genotypes in tables 10 and 11.

- Table 11:
  In the sofosbuvir trials, pegIFN alfa-2a was administered in the triple therapy however in the sofosbuvir licence both alfa-2a or alfa-2b may be administered. Please make this clear as this may impact cost-effectiveness. Note the same applies for simeprevir, telaprevir and boceprevir, and for all genotypes in subsequent tables.

- General comment:
  There is some inconsistent terminology in the ACD. For example in table 4 the term pegylated interferon is used however else where the terminology peginterferon alfa or peginterferon is used. We would suggest using peginteferon alfa throughout the document.

Roche Products Limited 6 Falcon Way
Shire Park
Welwyn Garden City
Hertfordshire
AL7 1TW

Health Economics and
Strategic Pricing

Tel. +44(0)1707 361032
Fax +44(0)1707 384123

We would be happy to provide further clarification if required.

Yours sincerely,

[redacted]

[redacted], [redacted] [redacted] [redacted] [redacted]

Roche Products Limited